Psychedelics and VR – Interview with David Glowacki

To better understand the science of psychedelics, and how we can make the bridge to implementing them in practice, Blossom is conducting a series of interviews with psychedelic scientists. Our editor-at-large, George Fejer, speaks to David Glowacki, one of the world’s leaders in the use of virtual reality applied to scientific simulation and visualization.

Taking Microdosing with a Pinch of Salt

Microdosing is becoming more popular every day. From Hollywood to small towns all across the word. Is there scientific merit to it, or all placebo? And does a new paper prove the benefits of microdosing?

Woven Science: Indigenous Communities

How can we marry psychedelic capitalism & reciprocity? | Blossom speaks to Woven Science on their approach to indigenous communities, how they can give back, and provide a template for others to do so.

Psychedelics Research Recap November 2021

November proved to be another productive month for psychedelic research. A variety of surveys looked at how psychedelics alter beliefs, reduce opioid use, and the effects of microdosing. A finished Phase I trial clear 5-MeO-DMT for the next step, cannabis intensifies a psychedelic experience, and psychedelics may help with Alzheimer’s.

Research Briefing: Improving psychedelic trials

In the Research Briefing of December 6th: 1) The methodological challenges faced in psychedelic clinical trials (and how to fix them) 2) Mystical experiences in recreational use associated with improvements in wellbeing 3) A novel 5-MeO-DMT formulation proves to be safe in Phase I trial

?>